Current Infectious Disease Reports

, Volume 7, Issue 2, pp 91–102

Management of hepatitis C in HIV-infected patients

  • Benigno Rodriguez
  • David A. Bobak

DOI: 10.1007/s11908-005-0067-0

Cite this article as:
Rodriguez, B. & Bobak, D.A. Curr Infect Dis Rep (2005) 7: 91. doi:10.1007/s11908-005-0067-0


As the survival of HIV-infected patients has been lengthening over the past 10 years as a consequence of effective antiretroviral therapy, hepatitis C virus (HCV) coinfection has emerged as a major cause of morbidity and mortality in this population. HCV/HIV coinfection is associated with accelerated progression of liver disease, untoward effects on the immunologic and virologic response to antiretroviral medications, and possibly with a more aggressive course of HIV disease. The results of major trials of combination therapy for HCV in coinfected patients have clearly established the combination of pegylated interferon-α with ribavirin as the treatment of choice in this population. However, the effectiveness and tolerability of this regimen remains suboptimal, particularly in patients with genotype 1 HCV infection. This paper reviews the impact of HCV coinfection in HIV-infected patients, outlines current concepts on management and antiviral treatment, and discusses some of the newer agents, currently in the therapeutic pipeline, that are directed against novel molecular targets.

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Benigno Rodriguez
    • 1
  • David A. Bobak
  1. 1.Division of Infectious DiseasesUniversity Hospitals of ClevelandClevelandUSA